| Accession |
PRJCA011508 |
| Title |
Phase I study to evaluate the safety and tolerability of the PD-L1 antibody SHR-1316 in patients with advanced malignancies |
| Relevance |
Medical |
| Data types |
Clinical, imaging, metabolic, biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the safety and tolerability of SHR-1316 monotherapy and standard chemotherapy in patients with advanced malignant tumors |
| Sample scope |
Multiisolate |
| Release date |
2022-08-29 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
| Organization |
Jiangsu Hengrui pharmaceutical Co.LTD |
| Submission date |
2022-08-29 |
